- Home
- DSP vs ALMS Comparison
DSP vs ALMS Comparison
Compare DSP & ALMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DSP
- ALMS
- Stock Information
- Founded
- DSP 1999
- ALMS 2021
- Country
- DSP United States
- ALMS United States
- Employees
- DSP N/A
- ALMS N/A
- Industry
- DSP EDP Services
- ALMS
- Sector
- DSP Technology
- ALMS
- Exchange
- DSP Nasdaq
- ALMS NYSE
- Market Cap
- DSP 291.3M
- ALMS 260.6M
- IPO Year
- DSP 2021
- ALMS 2024
- Fundamental
- Price
- DSP $13.28
- ALMS $7.24
- Analyst Decision
- DSP Strong Buy
- ALMS Strong Buy
- Analyst Count
- DSP 7
- ALMS 7
- Target Price
- DSP $23.29
- ALMS $28.17
- AVG Volume (30 Days)
- DSP 511.5K
- ALMS 1.3M
- Earning Date
- DSP 03-03-2025
- ALMS 05-15-2025
- Dividend Yield
- DSP N/A
- ALMS N/A
- EPS Growth
- DSP N/A
- ALMS N/A
- EPS
- DSP 0.14
- ALMS N/A
- Revenue
- DSP $289,235,000.00
- ALMS N/A
- Revenue This Year
- DSP $16.35
- ALMS N/A
- Revenue Next Year
- DSP $16.13
- ALMS N/A
- P/E Ratio
- DSP $93.04
- ALMS N/A
- Revenue Growth
- DSP 29.74
- ALMS N/A
- 52 Week Low
- DSP $7.77
- ALMS $3.18
- 52 Week High
- DSP $26.33
- ALMS $13.53
- Technical
- Relative Strength Index (RSI)
- DSP 40.81
- ALMS N/A
- Support Level
- DSP $11.40
- ALMS N/A
- Resistance Level
- DSP $13.48
- ALMS N/A
- Average True Range (ATR)
- DSP 0.69
- ALMS 0.00
- MACD
- DSP 0.32
- ALMS 0.00
- Stochastic Oscillator
- DSP 90.54
- ALMS 0.00
About DSP Viant Technology Inc.
Viant Technology Inc is an advertising software company. The software enables the programmatic purchase of advertising, which is the electronification of the advertising buying process. Through the technology, a marketer can easily buy ads on desktop, mobile, connected TV, linear TV, streaming audio and digital billboards.
About ALMS ALUMIS INC
Alumis Inc is a clinical-stage biopharmaceutical company focused on identifying, acquiring, and accelerating the development and commercialization of transformative medicines for autoimmune disorders. The Company leverages its proprietary precision data analytics platform, biological insights, and a team of experts with deep experience in precision medicine drug discovery, development, and immunology, to create medicines that significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies.